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Renal atrial natriuretic factor receptors in hamster cardiomyopathy.
Hamsters with cardiomyopathy (CMO), an experimental model of con-
gestive heart failure, display stimulated renin-angiotensin-aldosterone and
enhanced sympathetic nervous activity, all factors that lead to sodium
retention, volume expansion and subsequent elevation of plasma atrial
natriuretic factor (ANF) by the cardiac atria. However, sodium and water
retention persist in CMO, indicating hyporesponsiveness to endogenous
ANF. These studies were undertaken to fully characterize renal ANF
receptor subtypes in normal hamsters and to evaluate whether alterations
in renal ANF receptors may contribute to renal resistance to ANF in
cardiomyopathy. Transcripts of the guanylyl cyclase-A (GC-A) and gua-
nylyl cyclase-B (GC-B) receptors were detected by quantitative poly-
merase chain reaction (PCR) in renal cortex, and outer and inner
medullas. Compared to normal controls, the cardiomyopathic hamster's
GC-A mRNA was similar in cortex but significantly increased in outer and
inner medulla. Levels of GC-B mRNA were not altered by the disease. On
the other hand, competitive binding studies, autoradiography, and affinity
cross-linking demonstrated the absence of functional GC-B receptors in
the kidney glomeruli and inner medulla. Also, C-type natriuretic peptide
(CNP), the natural ligand for the GC-B receptors, failed to stimulate
glomerular production of its second messenger cGMP. In CMO, sodium
and water excretion were significantly reduced despite elevated plasma
ANF (50.5 11.1 vs. 309.4 32.6 pg/mI, P < 0.001). Competitive binding
studies of renal glomerular ANF receptors revealed no change in total
receptor density, B,ax (369.6 27.4 vs. 282.8 26.2 fmol/mg protein), nor
in dissociation constant, K,1 (647.4 79.4 vs. 648.5 22.9 pM). Also,
ANF-C receptor density (254.3 24.8 vs. 233.8 23.5 fmol/mg protein),
nor affinity were affected by heart failure. Inner medullary receptors were
exclusively of the GC-A subtype with Bmax (153.2 26.4 vs. 134.5 21.2
fmol/mg protein) and Kd (395.7 148.0 vs. 285.8 45.0 pM) not altered
by cardiomyopathy. The increase in ANF-stimulated glomerular cGMP
production was similar in normal and CMO hamsters (94- vs. 75-fold).
These results demonstrate that renal ANF receptors do not contribute to
the attenuated renal responses to ANF in hamster cardiomyopathy.
Atrial natriuretic peptide (ANF) is a cardiac hormone that
participates in the regulation of body fluid volume through
multiple mechanisms. The natriuretic and diuretic actions of ANF
result from enhanced glomerular filtration rate and/or reduced
tubular reabsorption of sodium and water, as well as suppression
of renin, aldosterone and vasopressin [1]. The biological actions of
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ANF are mediated by specific guanylyl cyclase receptors, GC-A
and GC-B, through generation of cGMP [2]. A third receptor,
ANF-C, mediates inhibition of endothelin release and antagonism
of the renin-angiotensin-aldosterone system [1] by inhibiting
cAMP [3]. ANF-C receptors may also promote clearance of the
peptide from the circulation [4].
In congestive heart failure (CHF), the enhanced activity of the
renin-angiotensin and the sympathetic nervous systems leads to
sodium retention and volume expansion, the primary stimulus for
ANF release by the cardiac atria. We [5] and others [6—11] have
shown that plasma ANF is elevated in CHF, and that the elevation
is influenced by increased contribution of the cardiac ventricles
[12] and lungs [51. However, despite elevated plasma levels in
CHF, salt and water retention persist, and the response to
exogeous infusion of ANF is blunted [9, 11, 13, 14]. Mechanisms
postulated for this blunted response include opposition by de-
creased renal perfusion pressure [15], stimulation of renin-angio-
tensin-aldosterone system and renal sympathetic nerve activity
[161 or receptor down-regulation. Down-regulation of ANF re-
ceptors in CHF has been shown to occur in hamster lung [17, 18],
human vascular beds [18] and platelets [19], but reports on renal
ANF receptors are controversial. ANF receptors were decreased
[20, 21], increased [22] or unchanged [11, 23] in glomeruli of
animals with experimental or genetic CHF. These differences may
be attributed to the various experimental designs, different models
of heart failure, severity of the disease [6] or methodologies
employed.
Most studies of the kidney have focused on total ANF receptors
in glomeruli. However, differential modification of the propor-
tions of ANF receptor subtypes at different segments of the
nephron, may lead to important physiological effects. Further-
more, the presence of GC-B mRNA is demonstrated in rat kidney
[24—26], but the sheep kidney does not exhibit functional GC-B
receptors [27]. Therefore, the aims of the present studies were (i)
to fully characterize renal ANF receptor subtypes at cortical and
medullary sites of the normal hamster kidney, and (ii) to evaluate
whether alterations in renal ANF receptors may contribute to the
renal resistance to ANF in moderate to severe cardiomyopathy.
Experiments were performed simultaneously on normal and
cardiomyopathic hamsters (CMO), using competitive binding,
autoradiography, cross-linking as well as stimulation of eGMP
production. Also, the renal distribution and regulation of GC-A
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and GC-B mRNAs were assessed by reverse transcription poiy-
merase chain reaction (RT-PCR).
Methods
Animals and tissue preparation
The cardiomyopathic hamsters (200 to 220 days old) originated
from the UM-X 7.1 myopathic line, which was established by
cross-breeding diseased animals from the original BlO 14.6
Golden Syrian hamster strain of the BIO-Research Institute
(Cambridge, MA, USA) with unrelated healthy hamsters. These
animals exhibit the same pathological changes in heart and
skeletal muscles originally found in their progenitors. Their main
advantage resides in the fact that the disease is rather homoge-
neous, with a predictable clinicopathological course starting with
cardiac lesions at 30 days of age, and developing moderate to
severe heart failure between 200 and 300 days [28]. At 200 days
cardiomyopathic hamsters have generalized edema and pleural
and abdominal effusion, altered liver size, color and firmness and
an increase of heart volume. Age-matched normal Golden Syrian
hamsters (Charles River, St. Constant, Quebec, Canada) served as
controls. Normal and CMO hamsters were kept in individual
metabolic cages at controlled room temperature under a 12 hours
dark:light cycle and free access to Purina laboratory food and tap
water. Daily water intake, urine excretion and body wt levels were
measured on two consecutive days, and urine samples were kept
for the determination of urinary sodium, potassium, ANF and
cGMP. The hamsters were sacrificed by decapitation, between
8:00 and 10:00 a.m. to exclude diurnal variations. Blood (1 ml) was
collected for plasma ANF measurement in prechilled tubes
containing protease inhibitors to a final concentration, EDTA
i0 M, phenyl methyl sulfonyl fluoride (PMSF) i0 M and
pepstatin-A 0.5 X i0 M.
The kidneys were rapidly excised and, for the autoradiographic
studies, were snap frozen in 2-methylbutane cooled by dry ice and
stored at —80°C. For the preparation of membranes, the kidneys
were placed in ice cold saline, decapsulated and dissected longi-
tudinally. The inner medulla was separated, frozen in liquid
nitrogen and stored at —80°C. The renal cortex was immediately
processed and glomeruli were isolated by graded sieving. For
membrane competitive binding and cross-linking studies, the
cortical tissue was passed through a 0.5 mm grid. The paste was
diluted with 0.9% saline and gently filtered by successive passage
through a 200, 150, 100 and 75 j.m nylon sieves. These steps were
repeated until a 90 to 95% pure preparation was obtained as
assessed by light microscopy. The glomeruli retained above the 75
tm sieve were washed and kept at —80°C in 50 mrvi Tris-HC1
buffer at pH 7.4. For stimulation of cGMP production, glomeruli
were similarly isolated from the renal cortex, except that saline
was substituted by freshly prepared oxygenated cold Kreb's buffer
at pH 7.4.
ANF was measured by radioimmunoassay (RIA) of vycor
extracted plasma and Sep-Pak extracted urine as described by
Gutkowska [29]. Urinary cGMP was measured directly by RIA
[301. Sodium and potassium excretions were measured by flame
photometry.
Preparation of glomerular and inner medullaiy membranes
Glomerular membranes were prepared by homogenization of
the glomeruli for one minute with a polytron followed by centrif-
ugation at 30,000 X g at 4°C for 20 minutes. Membranes were
resuspended in 50 mrvi Tris-HC1 buffer, pH 7.4, for immediate use
in competition binding radioreceptor assays.
Renal inner medullary membranes were prepared by homoge-
nization and differential centrifugation of the tissue in a freshly
prepared 50 mivi Tris-HCI buffer, pH 7.4, containing 3 mvi MgC12,
25 m sucrose, 1 ma EDTA and 5 mivi PMSF. The homogenates
were centrifuged twice at 1500 X g at 4°C for 20 minutes. The
supernatants were combined and centrifuged two times at 30,000
X g at 4°C for 45 minutes. The pellet was resuspended in 50 m'vi
Tris-HCI buffer, pH 7.4, aliquoted and stored at —80°C.
Protein concentrations of glomerular and medullary mem-
branes were determined spectrophotometrically by a modification
of Bradford, using BSA as standard.
Competitive binding assays
Optimal binding conditions (protein and time dependence)
were established in the membrane preparations, using freshly
prepared monoiodinated 1251-rANF and 1251-tyr°CNP, at room
temperature. Rat ANF(99_I26) (rANF) and tyr°CNP (Penninsula
Laboratories, Belmont, CA, USA) were iodinated by the lactoper-
oxidase method and purified by HPLC as previously described
[29].
Competition binding studies were performed simultaneously on
renal membranes obtained from normal and cardiomyopathic
hamsters. The assay buffer consisted of 50 mivi Tris-HCI buffer, pH
7.4, containing 0.1% bacitracin, 0.5 mrvi PMSF, 5 mM MgCI2, 25
mM MnC12, 1 mvi EDTA and 0.4% BSA. Aliquots of membrane
preparations were incubated at 22°C, with 20,000 cpm of 1251
rANF or '251-tyr°CNP, without and with increasing concentrations
(10 12 to 106 M) of specific displacing peptides, rANF(99_126),
c-type natriuretic peptide (CNP-22) and synthetic C-ANF(1021 21)
(Peninsula Laboratories) in a total volume of 0.2 ml. The reaction
was stopped by adding 3 ml of cold 50 mvt Tris-HCI buffer, pH 7.4,
and rapid filtration of the membrane bound tracer on Whatman
GF/C filters (Millipore, Mississauga, Ontario, Canada) presoaked
in 1% polyethylenimine (PEI). The filters were rinsed twice with
3 ml of 50 m'vi Tris-HC1 buffer, pH 7.4, dried and counted in a
Hewlett-Packard gamma counter. Binding in the presence of 10_6
M of the displacing peptides rANF, CNP and C-ANF(102_121) was
considered nonspecific.
Affinity cross-linking studies
Glomerular and inner medullary membranes (250 .tg of pro-
tein) were incubated with '251-rANF (10 cpm) in binding buffer
containing 50 m in Tris-HC1 buffer at pH 7.2, 0.2 ms PMSF, 20
jig/ml leupeptin, 20 ig/ml aprotinin, 10 mi MgCl2 and 30 mM
NaCI. Specificity of binding was determined by the addition of
i0 M rANF, CNP and C-ANF(102_121) to the reaction mixture.
After 90 minutes of incubation at 4°C, and centrifugation at
30,000 x g for 15 minutes, the pellet was resuspended in 250 l of
the binding buffer and 250 tl of distilled water. The receptors
were cross-linked by incubation for 30 minutes at 4°C with 25
pd/tube disuccinyl suberate (3.68 mg/mI in dimethyl sulfoxide).
Then the reaction was stopped by addition of 25 l ammonium
acetate and centrifugation at 30,000 X g for 15 minutes at 4°C.
The pellet was resuspended in sample buffer containing 2%
f3-mercaptoethanol, boiled for 10 minutes (denatured under
reducing conditions) and separated by polyacrylamide gel electro-
phoresis. High molecular weight standards ranging from 45 to 200
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kD (Biorad, Richmond, CA, USA) were used. The gel was stained
with Coomassie blue R-250, dried, exposed to a phosphor-
sensitive screen for three days then scanned with a Phosphorlm-
ager (Molecular Dynamics, Sunnyvale, CA, USA).
Stimulation of cGMP
The production of cGMP was stimulated by rANF and CNP, in
freshly isolated renal glomeruli of normal and CMO hamsters
simultaneously. Glomerular aliquots (100 g) were preincubated
in a 95% 02 and 5% CO2 atmosphere, at 37°C for 15 minutes,
then for two minutes in 10 mi isobutylmethyixanthene (IBMX).
Rat ANF and CNP were added to the aliquots in a final
concentration of 5 x 10_8 M, and incubated for 90 seconds. The
reaction was stopped by the addition of 2 ml of 1 N perchloric acid
and cooling in liquid N2. On the assay day, the samples were
sonicated for 15 seconds then centrifuged at 12,000 x g at 4°C.
cGMP was determined in the supernatants by radioimmunoassay
as previously described by Tremblay [301.
Autoradiography
Cryostat whole kidney sections (20 jim) from six normal and six
CMO hamsters, were cut and mounted on acid-washed gelati-
nized slides, then placed overnight in a partial vacuum at —4°C.
Slides were stored in boxes with Drierite at —80°C until the
autoradiographic procedures were performed [31]. Optimal bind-
ing conditions (amount of radiolabeled ligand and incubation
time) were determined in preliminary studies. Sections from
normal and CMO kidneys were assayed simultaneously. Duplicate
slides were brought to room temperature in incubation buffer
containing 50 mi Tris-HC1, pH 7.4, and 0.1% PEI for 15 minutes.
The effect of prior occupancy was eliminated by placing the slides
in acidic buffer (40 m sodium acetate, 150 mM NaCl, pH 5.0) for
10 minutes followed by washing with Tris-HC1 buffer at pH 7.4.
Then, the slides were incubated with 50 M 1251-rANF for one
hour at room temperature. The binding buffer consisted of 50 mM
Tris-HC1 buffer, pH 7.4, 150 mM NaCl, 40 mg/ml bacitracin, 0,5%
BSA, 0.2 m PMSF and 20 j.g/ml leupeptin. The sections were
washed four times, two minutes each, with ice-cold Tris-HCI
buffer, pH 7.4, at 4°C. The slides were finally rinsed with distilled
water to remove the salts and dried rapidly under a stream of cold
air.
Nonspecific binding was determined on adjacent sections under
identical incubation conditions except for the addition of 10—6 M
and iO M rANF. GC-B and ANF-C receptors were identified by
addition of io— M CNP and C-ANF(102_121), respectively. Local-
ization of the binding sites of CNP was also determined in sections
similarly incubated and displaced with CNP as above, but after
saturation of ANF-C receptors with iO M C-ANF(1(J2_121).
For direct evaluation of the GC-B receptors, another set of
slides were treated as above, except that the sections were
incubated with '251-tyr°CNP (100 pM) without and with displacing
peptides, rANF and C-ANF(102121) at 10 M, CNP at 106 M and
iO M as well as by i0— M CNP after saturation of the ANF-C
receptors with io M C_ANF(1o2_12j).
The dried tissue sections were exposed in phosphor-sensitive
cassette for 48 hours, then scanned, visualized and quantified by
Phosphorlmager (Molecular Dynamics).
RNA extraction
Kidneys of three normal and three CMO hamsters were
dissected and the inner medulla, outer medulla and cortex were
separated then placed in liquid N2 and stored at —80°C. Total
RNA was extracted by the acid guanidinum-thiocyanate-phenol-
chlorophorm method [32]. Additionally, RNA was treated with
DNAse I. The integrity of the preparations was verified by gel
electrophoresis and RNA concentrations were measured by UV
spectrophotometry.
First strand cDNA synthesis and quantification reaction product
Total RNA (2 jig) was annealed with 0.5 jig of random hexamer
and reverse transcribed in 50 mrvi Tris-HC1 buffer (pH 8.3),
containing 7 mrvi KCI, 3 mivi MgCl2, 10 msi DTT, 0.5 mM dNTP, 40
units RNAsin (Pharmacia Biotech, Uppsala, Sweden), 200 units
Moloney murine leukemia virus reverse transcriptase (Gibco
BRL, Burlington, Ontario, Canada), in total volume of 40 jil. The
reaction was incubated for one hour at 37°C. To reduce variation
in RNA input, length and quantification of the product, newly
synthesized cDNA was labeled by the addition of 1 jiCi/reaction
of 2500 Ci/mM 32P-dCTP (Amersham, Oakville, Ontario, Canada)
to mastermix. A 3 l aliquot of reverse-transcription reaction was
denatured at 95°C for five minutes and then electrophoresed on
1% agarose gel. The gel was dried on autoradiographic film and
counts over 400 bp in length were integrated for each sample
using Image-Quant analysis software (Molecular Dynamics). In-
put of cDNA samples in each PCR reaction was normalized
according to the measurements of radioactive reverse-transcrip-
tion reaction product [33].
Polymerase chain reaction (PCR) amplification of GC-A and
GC-B transcripts
cDNA preparations were mixed with fixed amount of mutated
DNA, containing mismatched bases, which create an EcoRl site
[24, 34]. PCR amplification was performed with the following
primers:
GC-A forward, 5 '-AGTGTII'ACCATCTACTFCAGTGATAT-
TGTG-3';
GC-A reverse, 5 '-CTCGAAACCATCGAACTCTlTCCAGCA-
CACAGC-3';
GC-B forward, 5 '-GGTACCAGCATATTGGACAACCTC-3';
GC-B reverse, 5 '-CAGGAGTCCAGGAGGTCCTITrTCG-3'.
A volume of 50 j.tl of 50 mtvt Tris-HC1 buffer (pH 8.4) containing
50 mM KCI, 1.5 mM MgCI2, 0.2 mrvi dNTPs, 40 pmol of each
primer, 2.5 units of Taq DNA polymerase (Gibco BRL) and 10
jiCi of 32P-dCTP was incubated for 30 cycles of one minute of
denaturation at 94°C, one minute annealing at 65°C, and two
minutes polymerization at 72°C. Ten microliters of each sample
were digested at 37°C for one hour with 10 units of EcoRI. The
digested samples were electrophoresed on 1.5% agarose gel that
gave upper non-digested bands derived from endogenous eDNA
(GC-A 474 bp, and GC-B 762 bp), and lower digested bands
derived from mutated cDNA (GC-A 283 bp and 191 bp; GC-B
385 and 377 bp, respectively).
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Table 1. Biochemical and hormonal parameters in normal and
cardiomyopathic (CMO) hamsters
Normal CMO
Body weight g 163.2 1.9 137.3 3.3"
Water intake mi/day 23.4 4.8 10.4 1.1"
Water intake mi/day/% body wt 14.3 2.9 7.5 0.6"
UV mi/day 9.1 3.0 2.0 0.4c
UV mi/day/% body wt
UNUV mmol/day
6.2 1.8
0.68 0.11
1.4 0.3'
0.33 0.05"
UNV mmol/day/% body wt 0.42 0.07 0.24 0.03"
UKV mmol/day 1.59 0.19 0.94 0.17"
UKV mmol/day/% body wt 0.97 0.11 0.68 0.11"
UGMp mmoi/day
UGMp mmol/day/% body wt
14.3 1.1
9.2 0.5
18.5 2.3
13.5 1.7"
UANF pg/day 2308 280 1462 275'
Upg/day/% body wt 1414 169 1064 196
Plasma ANF pg/mi 50.5 11.1 309.4 32.6"
Abbreviations are: % body wt, percent body weight; UV, urinary
volume; UNV, urinary sodium excretion, UKV, urinary potassium excre-
tion; UGMp, urinary cGMP excretion, UANF, urinary ANF excretion.
"p < 0.05 vs. normal, hp < 0.01 vs. normal, cp < 0.001 vs. normal
Data analysis
The equilibrium dissociation constant (Kd) and maximum bind-
ing capacity (B,,,,,) for the ligands used in the competitive binding
radioreceptor studies were calculated using the LIGAND com-
puter program (Elsevier-Biosoft, Cambridge, UK). Data storage,
graphical output and statistical analyses were accomplished using
RS1 data analysis software (BBN, Cambridge, MA, USA). All
data were assessed using analysis of variance followed by Bonfer-
roni's test for repeated measurements. Statistical significance was
taken as P < 0.05. All data are reported as mean SEM.
Results
Basal biochemical and hormonal parameters determined in 12
normal and 12 CMO hamsters are shown in Table 1. Compared to
their normal age-matched controls, the hamsters with moderate to
severe cardiomyopathy exhibited a reduced body weight, water
intake, urinary volume and excretion of sodium and potassium.
The reduction in volume and electrolyte excretion persisted after
normalizing the values to individual body weights. These changes
were accompanied by marked elevation in plasma ANF but
reduced urinary ANF (2308 280 vs. 1462 275 pg/mi, P <
0.05). Urinary cGMP tended to increase in CMO, but reached
significance after normalizing the levels to individual body weight
(9.2 0.5 vs. 13.5 1.7 nmol/day/% body wt, P < 0.01).
Competitive binding assays
Glomerular ANF receptors. Competitive binding assays were
performed by incubating 50 ig of glomerular membrane protein
with '251-rANF for two hours at room temperature. Figure 1
illustrates curves plotted from data of binding assays of glomeru-
tar membranes of CMO (N = 7 groups of 10 hamsters/group) and
corresponding normal hamsters (N = 7 groups), represented as
%B/B0, where B and B0 represent, respectively, binding with and
without displacing peptides. Bound '251-rANF was progressively
inhibited by increasing concentrations of rANF and to a lesser
extent by C-ANF(l2I2J) and CNP. These results indicate that the
glomerular receptors are of the guanylyl cyctase and the clearance
subtypes. The presence of GC-B receptor subtype was question-
able because the similarity of inhibition by CNP and
C-ANF(,02_,21) raised the possibility that CNP binding could have
been mediated by the ANF-C clearance receptors.
Kinetic parameters obtained from the displacement curves
revealed that, compared to normal controls, the cardiomyopathic
hamsters exhibited similar total glomerular ANF binding sites,
B,,,ax (369.6 27.4 vs. 282.8 26.2 fmol/mg protein), and
dissociation constant, Kd (647.4 79.4 vs. 648.5 22.9 pM). Also,
ANF-C receptor density (254.3 24.8 vs. 233.8 23.5 fmol/mg
protein) and affinity were not affected by heart failure.
Inner medulla.'y ANF receptors. Figure 2 illustrates curves ob-
tained from competitive binding receptor assays of renal inner
medullary membranes (70 gg) of six groups each (10 hamsters/
group) of normal and CMO hamsters. Increasing concentrations
of unlabeled rANF inhibited progressively binding of '251-rANF
to inner medullary membranes. But CNP and C-ANF(l02.,2I)
failed to inhibit binding and represented less than 10% at 10 M
concentrations. These results indicated that hamster inner med-
ullary membranes are exclusively of the GC-A receptor subtype.
Kinetic parameters obtained from the competitive binding curves
showed that (153.2 26.4 vs. 134.5 21.2 fmol/mg protein)
and Kd (395.7 148.0 vs. 285.8 45.0 pM) were not altered by
cardiomyopathy. On the other hand, under identical conditions
l25Ityr0CNP failed to bind to renal inner medutlary membranes
(data not shown), confirming the absence of GC-B receptors.
Autoradiographic studies
The results obtained from glomerular and inner medullary
membranes binding studies were further confirmed by autora-
diography. Figure 3 shows slices of whole kidneys obtained from
normal and CMO hamsters, where the blue to red colored scale
represents increasing binding. In the normal hamster, high 125J
rANF binding was shown in all the kidney structures, but was
mostly pronounced in cortical and inner medullaty regions.
Quantification by Phosphorlmager revealed that nonspecific bind-
ing in the cortex, determined in the presence of 106 M rANF was
less than 17% in both normal and CMO hamsters. In normal
hamsters, cortical binding was displaced by iO— M rANF, C-
ANFO2.l2!) and CNP and represented 77%, 48% and 55% of
total binding, respectively. Similar findings were obtained in the
CMO where cortical displacement with these peptides repre-
sented 85%, 48% and 49% of corresponding total cortical bind-
ing. Not shown in the Figure is that after saturation of the ANF-C
receptors with i0— M C-ANF(102_,21), CNP did not result in
further displacement. The equal displacement obtained with CNP
and C-ANF(102_121), and the lack of additive effect of CNP and
C-ANF(I0212I) suggest that both ligands were binding to the same
receptor, namely ANF-C.
High binding of 1251-rANF was observed at the inner medulla
and at the tip of the papilla (Fig. 3). Specific binding represented
80% of total inner medullary binding in normal and CMO
hamsters. But C-ANF(,02_,21) and CNP failed to displace bound
'251-rANF from inner medullary structures, consistent with the
absence of ANF-C and GC-B receptors (Fig. 3).
These results were further confirmed by using 1251-tyr°CNP as
the labeled ligand (Fig. 4). High specific binding of l2SItyr0CNP
was observed in the cortex, while binding was completely absent
from inner medulla. (Fig. 4). Cortical binding was equally dis-
placed by i0 M CNP, rANF and C-ANF(102_121) implying that
'251-tyr°CNP was binding to the ANF-C receptor.
0Log [peptide], M
Fig. 1. Competitive binding curves obtained by incubating renal glomerular membranes with '251-rANF for two hours at 22°C in the presence of increasing
concentrations (10-12 to 10' M) of rANF (•) and C-ANF11021211 (U) and CNP (A) in normal and cardiomyopathic (CMO) hamsters. Curves are plotted
as percent B/B, where B and B0 represent specific binding in the presence or absence of displacing peptides. Each point represents mean SCM of 7
determinations in duplicate.
Log [peptide], M
Fig. 2. Competitive binding curves obtained by incubating renal inner
medullaiy membranes with '251-rANF for two hours at 22°C in the presence
of increasing concentrations of unlabeled rANF in normal (S) and cardio-
myopathic (U) hamsters. Curves arc plotted as percent B/Br, where B and
B0 represent specific binding in the presence or absence of displacing
peptides. Each point represents mean SEM of 6 determinations in
duplicate.
Affinity cross-linking
The identity of glomerular ANF receptors was verified by
performing affinity cross-linking of renal glomerular membranes
(Fig. 5) of normal (lanes 1 to 4) and CMO (lanes 5 to 8) hamsters.
Figure 5 shows the presence of two bands corresponding to
molecular weights 130 and 66 kD (lanes 1 and 5). The high
molecular weight bands were inhibited by i07 M rANF (lanes 2
and 6), but not by i0 M CNP (lanes 3 and 7), nor iO M
C-ANF(102_lal) (lane 4 and 8). On the other hand, the low
molecular weight bands were inhibited by rANF (lanes 2 and 6),
and C-ANF(]oa_12]) (lane 4 and 8), but not by CNP (lanes 3 and
7). These results indicate that glomeruli exhibit GC-A and ANF-C
but not GC-B receptors. The third band below the 66 kD was not
displaced by the peptides and may be nonspecific.
Cross-linking of inner medullary membranes (Fig. 6) of normal
(lanes 1 to 4) and CMO hamsters (lanes 5 to 8), revealed the
presence of one band corresponding to the high molecular weight
ANF receptor (130 kD). The band was displaced by rANF (lanes
2 and 6) but not by C-ANF(1O2121) (lanes 3 and 7) nor CNP (lanes
4 and 8) at iO M concentrations.
In vitro stimulation of cGMP production
Baseline cGMP production from isolated glomeruli obtained
from 3 groups of normal and CMO animals, tended to be less in
CMO (0.27 0.09 vs. 0.17 0.04 pmol/mg protein). Upon
stimulation with 5 x iO M rANF, cGMP production was
significantly less in CMO (16.57 1.31 vs. 11.37 0.83 pmol/mg
protein, P = 0.02). However, when the data were presented as
percent increase from basal levels, the increase in normal ham-
sters was not significantly diffrent from that in CMO (94- vs.
75-fold). On the other hand, CNP at S x 108 M concentration
failed to stimulate cGMP production in glomeruli of normal (0.26
0.09 pmol/mg protein) and CMO hamsters (0.11 0.02
pmol/mg protein) confirming the absence of functional GC-B
receptors.
mRNA of GC-A and GC-B receptors
The presence of GC-A and GC-B mRNA was detected by
RT-PCR throughout the kidney regions, cortex, outer and inner
medulla. Figure 7 shows representative Phosporlmager density
bands of PCR products after EcoRI digestion and gel electro-
phoresis. Among the segments, inner medulla showed highest
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Fig. 3. Autoradiography of whole kidney binding to '251-rANF in normal
(A.E) and cardiomyopathic (F.J) hamsters. Total binding (A and F),
inhibition with 1O6 at rANF (B and C), 1O M rANF (C and H), iO M
CNP (D and I) and io C-ANF(102_121) (E and J). Reproduction of this
figure in color is made possible by a grant from Pfizer Canada, Inc.,
Quebec, Canada.
Fig. 4. Autoradiography of whole kidney binding to 1251-iyr°CNP in normal
(A-E) and cardiomyopathic (F-J) hamsters. Total binding (A and F),
inhibition with CNP at 10-6 M (B and U) and io at (C and H), iO at
C-ANF(10212!) (D and I), 1O M rANF (E and J). Reproduction of this
figure in color is made possible by a grant from Pfizer Canada, Inc.,
Quebec, Canada.
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Fig. 5. Affinity cross-linking of'251-rANF to renal glomenilar membranes of normal (lanes 1 to 4) and cardiomyopathic (lanes 5 to 8) hamsters in the absence
(lanes 1 and 5) and presence of iO7M rANF (lanes 2 and 6), CNP (lanes 3 and 7) and C-ANF(102_;21) (lanes 4 and 8). Two bands corresponding to 120
kD and 66 kD molecular mass were observed.
Fig. 6. Affinity cross-linking of 1251-rANF to renal inner medulla,y membranes of normal (lanes 1 to 4) and cardiomyopathic hamsters (lanes 5 to 8) in the
absence (lanes landS) and presence of io-M rANF (lanes 2 and 6), CNP (lanes 3 and 7) and C-ANF(10212]) (lanes 4 and 8). A single band corresponding
to the high molecular weight standard (120 kD) was observed.
signal of GC-A mRNA, while GC-B mRNA was equally expressed
in the various segments. Quantification of the bands revealed that,
compared to normal controls, the cardiomyopathic hamster GC-A
mRNA was similar in cortex but significantly increased in outer
and inner medulla. However, the levels of GC-B transcripts were
not altered by the disease.
Discussion
The present studies show that despite the expression of GC-B
receptors, the hamster kidney lacks functional GC-B receptors.
Renal glomeruli exhibit GC-A and ANF-C, while the inner
medullaiy receptors are exclusively of the GC-A subtype. These
findings are shown by competitive binding, affinity cross-linking,
autoradiography and by in vitro stimulation of cGMP production.
In CMO, the level of GC-A transcript is enhanced in outer and
inner medullary regions, but kinetic parameters (density and
affinity) and biological activity (cGMP production) of renal ANF
receptors are not altered.
Three ANF receptors have been identified by molecular cloning
and sequence analysis 1, 35]. Two subtypes, GC-A and GC-B
have a large extracellular binding domain and an intracellular
guanylyl cyclase domain within a single polypeptide chain of 120
to 140 kD. Distinction between these receptors is based on their
ligand selectivity. GC-A shows higher affinity to ANF, while GC-B
binds CNP preferentially [1, 35]. The third, ANF-C receptor
which is most widely distributed of the three ANF receptors,
consists of a large extracellular domain and a short cytoplasmic
tail that lacks the cyclase activity. ANF-C forms a homodimer that
can be reduced to —66 kD molecular mass with f3-mercaptoetha-
nol. ANF-C receptor shows less structural requirements, as it
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binds to all the natriuretic peptides and ANF metabolites, but
shows higher affinity to C-ANF(0)2_121), a synthetic 5 amino acid
deleted ring ANF analog [4, 35].
Our present findings confirm that the kidney cortex and papilla
are rich in ANF binding sites [41 and that the cortex possesses
both guanylyl cyclase receptors and clearance receptors, while the
inner medulla possesses only guanylyl cyclase ANF receptors [1,
27, 35]. In addition, the present detection of GC-A and GC-B
transcripts in all regions of the hamster kidney is consistent with
the widespread distribution of GC-A and GC-B mRNA detected
by PCR throughout the rat nephron [24, 25, 36]. However, using
competitive binding receptor assays, autoradiography, cross-link-
ing as well as in vitro stimulation of cGMP production, we
demonstrate the absence of functional GC-B receptors from
hamster glomeruli and inner medulla. This finding does not
necessarily contradict our present finding and earlier reports of
the presence of GC-B transcripts in the kidney. The level of
Fig. 7. Representative Phosphorlmager density
bands of PCR products after EcoRl digestion and
get electrophoresis of GC-A and GC-B mRNA
detected in renal cortex, outer and inner medulla
of normal and cardiomyopathic hamsters. The
upper non-digested bands represent
endogenous cDNA (GC-A, 474 bp; GC-B, 762
bp). Lower digested bands represent mutated
eDNA (GC-A, 283 and 191 bp; GC-B, 385 and
377 bp, respectively). Results are presented as
bar graphs and expressed as percentage of the
sum of two bands taken as 100% for each
amplified sample from 3 determinations.
Symbols are: (•) normal; (E) CMO.
expression does not always correlate with the number of func-
tional cell surface receptors [371, since mRNA level is not the only
determinant of the amount and function of the protein. Other
factors involved include translational efficiency, protein process-
ing and turnover, transport and insertion into the plasma mem-
brane [341 On the other hand, the lack of correlation may be also
attributed to the sensitivity of the techniques used. Yamamoto et
al [38] were able to detect GC-B mRNA along the bovine kidney
nephron using RT-PCR, but not by in situ hybridization. Conse-
quently, it is possible that the binding assays, autoradiography,
cross-linking and stimulation of cGMP production, may have
failed to detect very low amounts of the receptor whose transcript
was detected by PCR amplification. However, consistent with the
present results, the dissociation between GC-B mRNA levels and
activity of GC-B in stimulating cGMP production was also
observed in vascular smooth muscle cells [34], and in uterine
tissue [39]. Furthermore, whereas the presence of functional renal
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GC-B receptors in rats is controversial [36, 40, 41], the lack of
measurable amounts of GC-B receptors was shown in renal
glomeruli of sheep [27] and recently in hamsters [41].
Similar to previous observations in humans [8, 9] and experi-
mental animals [10, 11, 23], the cardiomyopathic hamsters in the
present study showed reduced diuresis and natriuresis and ele-
vated plasma ANF, suggesting an inability to excrete excess
sodium and a decrease in renal responsiveness to endogenous
ANF. The renal resistance to ANF in cardiomyopathy cannot be
explained by reduced activity of the peptide. Since urinary cGMP,
the biological marker of ANF activity [421, was significantly
elevated, a finding confirmed by others [10]. The dissociation
between ANF-induced urinary cGMP and sodium excretion also
observed in young rats [43], could reflect an overactive but
inadequate ANF system, probably due to altered hemodynamics
and neurohumoral reflexes in CHF.
The mechanisms underlying the hyporesponsiveness to ANF
may also include receptor down regulation. Elevated plasma
angiotensin II and enhanced renal nerve activity in CMO should
result in down-regulation of ANF receptors [44]. Contrary to our
expectations, competitive binding, affinity cross-linking and auto-
radiographic studies showed that ANF receptors at glomerular
and inner medullaty sites are not changed in cardiomyopathic
hamsters. These results are in agreement with Bianchi et al [7] and
with Isnard et a! [11] who reported that glomerular ANF recep-
tors are not altered by moderate to severe cardiomyopathy in the
hamster [7], and experimental CHF in the rabbit [11]. In contrast,
Cachofeiro et al [22] reported up-regulation in glomerular ANF
receptors in cardiomyopathic hamsters. The increased receptor
density reported in the latter study was accompanied by reduced
affinity, which should result in no net change in ANF receptor
binding capacity, and therefore would be similar to the present
results. This observation was later confirmed by the same group
[23] in rats with CHF caused by A-V shunt. On the other hand,
our present findings do not confirm previous reports showing
decreased inner medullaiy ANF receptors in rats with chronic
heart failure [21, 45].
Glomeruli of CMO hamsters showed reduced in vitro produc-
tion of cGMP, at baseline and after stimulation with ANF, which
may suggest an absolute down-regulation of the glomerular
receptors occurring at the second messenger level. But the
reduction disappeared when cGMP production was normalized to
basal levels, suggesting an intact receptor sensitivity [11]. The
possibility of a mechanism distal to the production of cGMP
appears to be very likely. Valentin et al [461 demonstrated that the
blunted natriuretic response to volume expansion and hence
elevated endogeous ANF in experimental nephrotic syndrome in
rats, resulted from enhanced hydrolysis of cGMP by the enhanced
phosphodiesterase activity. This effect was reversed by phospho-
diesterase inhibitors [46].
Urinary ANF was reduced in CMO hamsters and correlated
with the diminished sodium excretion, but not with elevated
plasma ANF nor with the enhanced urinary cGMP excretion. We
are presently unable to explain this result. However, reduced
urinary ANF may reflect reduction in urodilatin, the renal natri-
uretic peptide. Urodilatin shares with ANF the carboxyterminus
[351 that is recognized by our RIA antibody [29], but differs by 4
amino acid extended amino terminus, that has no effect on its
immuoreactivity. We have shown in an earlier study in the sheep,
that plasma ANF does not appear in urine in an intact form [47],
because of the unsaturable and high peptidase activity (NEP)
present in the brush border of the renal proximal tubule [48].
Urodilatin, secreted at the inner medullaiy sites [49] binds to and
activates renal ANF receptors [50], but unlike ANF, it escapes this
enzymatic degradation [51]. Further studies are required to clarify
the role of urodilatin in CHF but a plausible possibility is that for
more efficient conservation of volume, suppression of urodilatin
and other natriuretic peptides in CHF may further reduce the
natriuretic responses to ANF. Reduction in renal kinins were
reported to mediate renal resistance to ANF in sodium-retaining
chronic caval dogs [52].
Taken together, the unchanged to over-expressed GC-A recep-
tors as well as the intact second messenger system, may suggest
that the renal ANF system is preserved in CHF. The attenuation
of renal responses to ANF may be explained by reduced delivery
of ANF to the distal nephron [52], the overriding effects of
diminished renal perfusion pressure [15] and the antagonistic
actions of angiotensin II [53, 54], as well as decreased production
of intrarenal urodilatin, all factors that favor sodium reabsorption.
In acute CHF in dogs, restoring renal perfusion pressure restored
the renal natriuretic response to ANF [15]. Intrarenal infusion of
angiotensin II attenuated the natriuretic response to ANF [531
problably by stimulating the hydrolysis of cGMP by a Ca2-
activated cGMP phosphodiesterase [46, 54]. Also, infusion of
urodilatin in rats, produced significant dose-dependent increases
in urinary flow, glomerular filtration rate, and in absolute and
fractional sodium excretions [10].
In summary, the present studies demonstrate the absence of
functional GC-B receptors in glomeruli and inner medulla of the
hamster kidney. Also, the renal ANF system is shown to be intact
in hamster cardiomyopathy. The renal resistance to ANF may be
secondary to the opposing actions of reduced pressure and
enhanced angiotensin II activity and/or to an intracellular defect
beyond the second messenger system. Further studies are re-
quired to clarify whether a post-receptor defect exists in cardio-
myopathy.
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